| Tbio | RelA-associated inhibitor |
Regulator that plays a central role in regulation of apoptosis and transcription via its interaction with NF-kappa-B and p53/TP53 proteins. Blocks transcription of HIV-1 virus by inhibiting the action of both NF-kappa-B and SP1. Also inhibits p53/TP53 function, possibly by preventing the association between p53/TP53 and ASPP1 or ASPP2, and therefore suppressing the subsequent activation of apoptosis.
IASPP is one of the most evolutionarily conserved inhibitors of p53 (TP53; MIM 191170), whereas ASPP1 (MIM 606455) and ASPP2 (MIM 602143) are activators of p53.[supplied by OMIM, Mar 2008]
IASPP is one of the most evolutionarily conserved inhibitors of p53 (TP53; MIM 191170), whereas ASPP1 (MIM 606455) and ASPP2 (MIM 602143) are activators of p53.[supplied by OMIM, Mar 2008]
Comments
| Disease | Target Count | P-value |
|---|---|---|
| malignant mesothelioma | 3232 | 2.0e-08 |
| pituitary cancer | 1972 | 5.7e-07 |
| posterior fossa group A ependymoma | 468 | 4.4e-06 |
| interstitial cystitis | 2312 | 1.9e-03 |
| colon cancer | 1478 | 2.9e-03 |
| aldosterone-producing adenoma | 665 | 9.0e-03 |
| active ulcerative colitis | 764 | 1.2e-02 |
| pancreatic ductal adenocarcinoma liver metastasis | 1962 | 1.2e-02 |
| cutaneous lupus erythematosus | 1057 | 1.4e-02 |
| esophageal adenocarcinoma | 737 | 3.0e-02 |
| spina bifida | 1074 | 3.3e-02 |
| Disease | log2 FC | p |
|---|---|---|
| active ulcerative colitis | 1.028 | 1.2e-02 |
| aldosterone-producing adenoma | -1.040 | 9.0e-03 |
| colon cancer | 1.100 | 2.9e-03 |
| cutaneous lupus erythematosus | -1.400 | 1.4e-02 |
| esophageal adenocarcinoma | -1.500 | 3.0e-02 |
| interstitial cystitis | -1.400 | 1.9e-03 |
| malignant mesothelioma | 2.500 | 2.0e-08 |
| pancreatic ductal adenocarcinoma liver m... | 1.216 | 1.2e-02 |
| pituitary cancer | -1.100 | 5.7e-07 |
| posterior fossa group A ependymoma | 1.200 | 4.4e-06 |
| spina bifida | -2.020 | 3.3e-02 |
MDSEAFQSARDFLDMNFQSLAMKHMDLKQMELDTAAAKVDELTKQLESLWSDSPAPPGPQAGPPSRPPRY 1 - 70 SSSSIPEPFGSRGSPRKAATDGADTPFGRSESAPTLHPYSPLSPKGRPSSPRTPLYLQPDAYGSLDRATS 71 - 140 PRPRAFDGAGSSLGRAPSPRPGPGPLRQQGPPTPFDFLGRAGSPRGSPLAEGPQAFFPERGPSPRPPATA 141 - 210 YDAPASAFGSSLLGSGGSAFAPPLRAQDDLTLRRRPPKAWNESDLDVAYEKKPSQTASYERLDVFARPAS 211 - 280 PSLQLLPWRESSLDGLGGTGKDNLTSATLPRNYKVSPLASDRRSDAGSYRRSLGSAGPSGTLPRSWQPVS 281 - 350 RIPMPPSSPQPRGAPRQRPIPLSMIFKLQNAFWEHGASRAMLPGSPLFTRAPPPKLQPQPQPQPQPQSQP 351 - 420 QPQLPPQPQTQPQTPTPAPQHPQQTWPPVNEGPPKPPTELEPEPEIEGLLTPVLEAGDVDEGPVARPLSP 421 - 490 TRLQPALPPEAQSVPELEEVARVLAEIPRPLKRRGSMEQAPAVALPPTHKKQYQQIISRLFHRHGGPGPG 491 - 560 GPEPELSPITEGSEARAGPPAPAPPAPIPPPAPSQSSPPEQPQSMEMRSVLRKAGSPRKARRARLNPLVL 561 - 630 LLDAALTGELEVVQQAVKEMNDPSQPNEEGITALHNAICGANYSIVDFLITAGANVNSPDSHGWTPLHCA 631 - 700 ASCNDTVICMALVQHGAAIFATTLSDGATAFEKCDPYREGYADCATYLADVEQSMGLMNSGAVYALWDYS 701 - 770 AEFGDELSFREGESVTVLRRDGPEETDWWWAALHGQEGYVPRNYFGLFPRVKPQRSKV 771 - 828 //
